Last reviewed · How we verify
PMN310
At a glance
| Generic name | PMN310 |
|---|---|
| Sponsor | ProMis Neurosciences, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) (PHASE1)
- A Phase 1a Study of PMN310 In Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PMN310 CI brief — competitive landscape report
- PMN310 updates RSS · CI watch RSS
- ProMis Neurosciences, Inc portfolio CI